Ethical and regulatory frameworks for stem cell research in the MENA region

Stem cell research holds immense potential in revolutionizing medicine, offering the possibility to treat previously incurable conditions and advance regenerative medicine. Stem cell research has made significant strides globally since its inception in the mid-20th century. The discovery of stem cells dates back to the 1960s when Canadian scientists Ernest McCulloch and James Till first identified the regenerative potential of stem cells, a finding that sparked a revolution in medical research. Over the decades, stem cell research has evolved from studying basic cell biology to developing complex therapeutic approaches, including regenerative medicine, treatment of degenerative diseases, and personalized medicine. The discovery of induced pluripotent stem cells (iPSCs) in 2006 by Shinya Yamanaka further accelerated the field, providing a new avenue to generate stem cells without the ethical concerns associated with embryonic stem cells.

In the MENA region, stem cell research has gained increasing importance due to its potential to address the region’s unique health challenges. The Middle East and North Africa face a high prevalence of genetic disorders, such as thalassemia and sickle cell anemia, as well as lifestyle-related diseases like diabetes and cardiovascular conditions. Stem cell research presents a promising avenue for developing innovative treatments for these diseases. Countries like Saudi Arabia, the United Arab Emirates (UAE), Egypt, and Qatar have invested significantly in stem cell research over the past decade, driven by government initiatives, partnerships with international institutions, and the establishment of specialized research centers.

In the MENA region, this field is increasingly gaining attention, driven by both the promise of medical breakthroughs and the challenges posed by regulatory and ethical considerations. Understanding the ethical and regulatory frameworks that govern stem cell research in this region is crucial for fostering innovation while ensuring compliance and public trust.

Several key institutions in the MENA region are at the forefront of stem cell research:

• King Abdullah International Medical Research Center (KAIMRC), Saudi Arabia: Focuses on translational stem cell research, particularly in the areas of regenerative medicine and the treatment of hematological diseases.
• Qatar Biomedical Research Institute (QBRI): Engaged in research on stem cell therapy for cancer and diabetes, neurodevelopmental disorders, cancer, and genomics aiming to position Qatar as a leader in biomedical research in the region.
• Zayed Center for Health Sciences, UAE: Supports research initiatives in regenerative medicine and is exploring the use of stem cells for treating various chronic conditions.
• National Research Centre (NRC), Egypt: Conducts pioneering research in regenerative medicine, focusing on stem cell therapy for liver diseases and neurodegenerative disorders.

These institutions are working in collaboration with global partners to advance stem cell research and develop new therapies tailored to the specific needs of the region.

Regulatory Frameworks across the MENA Region

The regulatory landscape for stem cell research in the MENA region varies widely from country to country, reflecting diverse national priorities, legal systems, and levels of scientific development. While some countries have established comprehensive frameworks, others are in the nascent stages of regulatory development.

Saudi Arabia

In Saudi Arabia, stem cell research is governed by a combination of ethical guidelines and regulatory frameworks established by the National Committee of Bioethics (NCBE) and the Saudi Food and Drug Authority (SFDA).

The NCBE plays a crucial role in overseeing bioethical standards in research, including stem cell studies. It ensures that research adheres to ethical principles and guidelines, particularly in the context of human subjects. The SFDA is responsible for the regulation of biological products, including stem cells. It ensures the safety, quality, and efficacy of stem cell therapies and mandates that any biological products intended for marketing in Saudi Arabia must receive marketing authorization following a comprehensive review process [1].

A significant religious ruling, known as a fatwa, issued in 2003, permits the use of stem cells for therapeutic and scientific research, provided they are sourced from specific permissible origins. This fatwa outlines the ethical boundaries for stem cell research in the Kingdom, emphasizing the importance of obtaining cells from acceptable sources and prohibiting others. Under the 2003 fatwa, it is permissible to obtain, grow and use stem cells for therapeutic or scientific research purposes only if they are obtained from one of the following sources:

• Adults, if consent is obtained and no harm comes to them as a result of collection
• Children, if parental consent is obtained and no harm comes to child as a result of collection
• Placenta or umbilical cord with parental consent
• Embryos or fetuses that have been miscarried on their own accord or aborted for therapeutic reasons allowed by Sharia law, and parental consent is obtained
• Leftover fertilized embryos from in vitro fertilization that are donated by the parents.

However, under the 2003 fatwa, it is not allowed to obtain and use stem cells if taken from the following sources:

• Willfully aborted fetuses and fetuses aborted without a medical reason permitted by Sharia law
• Willfully fertilized donated ovum and sperm
• Therapeutic cloning [2]

United Arab Emirates

The regulatory framework for stem cells in the United Arab Emirates (UAE) is multifaceted, primarily governed by the Ministry of Health and Prevention (MoHAP) and local health authorities, such as the Department of Health in Abu Dhabi and the Dubai Health Authority. This framework aims to ensure the safety, efficacy, and ethical application of stem cell therapies across the country.

Nevertheless, only two Emirates lead regulation of the stem cells and cell products, which have established public guidelines for the regulated sector. These current standards are applied to the Dubai healthcare sector: “Platelet Rich Plasma Guidelines” (DHA, 2014) and “Standards for autologous adipose-tissue derived stem cells/stromal vascular fraction cells therapy” (DHA, 2020).

For Abu Dhabi healthcare stakeholders, the following have been issued: “DOH standard on stem cell therapies, products and regenerative medicine” (2019) and the “DOH standard for centers of excellence in hematopoietic stem cell transplantation services for adults and pediatrics” (2019).

These regulatory frameworks have represented a milestone regarding the research and preclinical or clinical applications of stem cell-based therapies and cell-derived products in both Dubai and Abu Dhabi in recent years. In addition, these standards have adopted international scientific evidence and good practices to enhance the high-quality services related to the collection, processing, and administration requirements. Controversially, as there are no national standards to follow, the framework needs to be updated to harmonize the relevant policies, regulations, and ethics for human research in the UAE [3].

Egypt

Egypt maintains ethical guidelines and regulatory oversight mechanisms to protect the rights and well-being of patients involved in stem cell clinical trials. Regulatory bodies ensure transparency, accountability, and adherence to international best practices in stem cell research. Regulatory oversight is provided by the Egyptian Drug Authority, which ensures compliance with ethical guidelines and international standards. Egypt’s regulatory framework also aligns with Islamic principles, requiring ethical review and informed consent for all research involving human tissues.

Jordan

Jordan has established itself as a regional leader in stem cell research, particularly in regenerative medicine and cellular therapy. In 2014, Jordan passed the Stem Cell Statute, the first of its kind in the region, which aims to regulate the use of stem cells for both therapeutic and research purposes. The Statute adopts a balanced approach between restrictive and intermediate regulations. The Jordanian Food and Drug Administration (JFDA) oversees the regulation of stem cell research, with guidelines that emphasize patient safety, ethical conduct, and transparency. Jordan permits the use of adult stem cells but has strict regulations against the use of embryonic stem cells, reflecting the country’s adherence to ethical norms that respect the sanctity of human life [4].

Algeria and Morocco

In Algeria and Morocco, the regulatory frameworks for stem cell research are still developing. While there is an interest in advancing stem cell therapies, both countries face challenges such as limited funding, lack of specialized research infrastructure, and the need for clearer regulatory guidelines. Nonetheless, there are efforts underway to establish ethical and regulatory standards in line with international norms.

Key Challenges in the MENA Region

Despite the progress made, several challenges remain for the ethical and regulatory oversight of stem cell research in the MENA region:

1. Harmonization of Regulations:

There is a significant lack of harmonization in regulatory frameworks for stem cell research across MENA countries. This fragmentation can hinder cross-border collaboration, slow down research progress, and make it difficult for researchers and companies to navigate the regulatory landscape.

For example, Saudi Arabia and UAE have relatively advanced frameworks for stem cell research, but these frameworks differ significantly. Saudi Arabia’s regulations are managed by the SFDA, while the UAE has its own set of guidelines under the Ministry of Health and Prevention. This disparity can complicate collaborative efforts and the standardization of research practices.

Moreover, as Egypt and Jordan have less developed regulations, it does not align with more advanced systems in the Gulf States. This inconsistency can create barriers for researchers aiming to collaborate across borders or seek funding from international sources.

2. Limited Public Awareness

Public understanding of stem cell research is often limited, which can lead to misconceptions and resistance. Raising awareness through education and public engagement is crucial. A study conducted in Saudi Arabia revealed that while 90.71% of participants expressed a desire to learn more about stem cell therapy, over half were unfamiliar with the concept. Additionally, 50.41% of respondents had concerns about the safety of stem cell treatments. This highlights a significant gap in public knowledge and trust, indicating the need for educational initiatives to improve understanding and acceptance of stem cell therapies [5].

3. Limited Ethical Review Infrastructure

Many MENA countries lack robust ethical review boards or Institutional Review Boards (IRBs) equipped to handle the complex ethical issues involved in stem cell research. This lack of infrastructure makes it difficult to ensure that research complies with both local and international ethical standards. Countries like Qatar and Saudi Arabia have established national ethics committees, others, such as Libya and Yemen, lack formalized systems for ethical oversight. This absence creates gaps in accountability and can lead to unethical practices, such as inadequate informed consent procedures or the exploitation of vulnerable populations.

4. Religious and Cultural Considerations

Ethical views on stem cell research, particularly embryonic stem cell research, are heavily influenced by religious beliefs in the MENA region. While Islamic law (Sharia) generally permits research on adult stem cells, embryonic stem cell research is more contentious due to concerns about the moral status of the embryo. In countries like Egypt and Iran, the use of embryonic stem cells is subject to strict ethical oversight, reflecting religious and cultural sensitivities. In contrast, countries like Jordan and Tunisia may be more permissive but still face public and clerical opposition. This religious influence often results in self-censorship among researchers and limits the scope of their studies.

Conclusion

Stem cell research in the MENA region represents a promising frontier for medical innovation, offering the potential to address some of the most pressing health challenges faced by the region, such as genetic disorders, degenerative diseases, and organ failure. The rapidly evolving field of stem cell research holds significant promise for developing novel therapies and regenerative treatments that could transform healthcare outcomes. However, advancing this field requires a careful balance between fostering scientific progress and adhering to ethical standards deeply rooted in cultural, religious, and societal values.

Countries like Saudi Arabia, the UAE, Egypt, Jordan, and Algeria are making significant strides in establishing and developing regulatory frameworks that govern stem cell research and its clinical applications. However, there remains considerable variation in the scope, implementation, and enforcement of these frameworks across the region. For instance, while some countries have developed detailed regulations and guidelines that address the use of human embryonic stem cells, others still lack comprehensive policies, creating inconsistencies that can hinder regional collaboration and limit research potential.

To realize the full potential of stem cell research in the MENA region, it is essential to foster a collaborative environment where scientific, ethical, and regulatory considerations are aligned. This would involve not only refining and harmonizing regulatory frameworks across different countries but also engaging in continuous dialogue with religious scholars, bioethicists, and community leaders to ensure that the research is conducted in a manner that respects and integrates cultural and ethical sensitivities. It is also crucial to promote public awareness and understanding of stem cell science to build trust and acceptance, which can be achieved through educational campaigns, transparent communication of research findings, and involvement of the public in discussions about the ethical implications of this work. By addressing these challenges, the MENA region can position itself as a leader in ethical and innovative stem cell research, contributing significantly to global advancements in regenerative medicine while respecting its unique cultural and ethical landscape.

Bibliography

[1]        Mahmoud, “Islamic Bioethics: National Regulations and Guidelines of Human Stem Cell Research in the Muslim World ,” 2022. https://digitalcommons.chapman.edu/cgi/viewcontent.cgi?article=1015&context=international_studies_theses (accessed Sep. 02, 2024).

[2]        Association for the Advancement of Blood & Biotherapies, “Saudi Arabia,” 2022. https://www.aabb.org/regulatory-and-advocacy/regulatory-affairs/regulatory-for-cellular-therapies/international-competent-authorities/saudi-arabia (accessed Sep. 02, 2024).

[3]        Castillo-Aleman, Ventura-Carmenate, Rivero-Jimenez, and Bencomo-Hernandez, “Regulatory Prospects of Clinical Trials with Stem Cells in the United Arab Emirates,” 2024. https://clinmedjournals.org/articles/ijscrt/international-journal-of-stem-cell-research-and-therapy-ijscrt-8-073.php?jid=ijscrt (accessed Sep. 02, 2024).

[4]        Al-Tabba’, Dajani, and Al-Hussaini, “Stem Cell Statute in Jordan: Leading the Way – PMC,” 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379862/ (accessed Sep. 02, 2024).

[5]        Aboalola, Ramadan, Baadhaim, Alsiary, and Badraiq, “Public awareness and understanding of stem cell treatments available in Saudi Arabia and their trust in hospitals and research centers involved in stem cell research-a cross sectional study – PubMed,” 2024. https://pubmed.ncbi.nlm.nih.gov/38628851/ (accessed Sep. 02, 2024).